The present technology provides methods for preparing a flowable amniotic composition derived from amniotic membrane of humans. Various embodiments of the method for preparing the amniotic composition may comprise mincing the amniotic membrane in a cryopreservation solution, cryopreservation, homogenization, filtration, centrifugation, and resuspension of a pellet in a cell solution to produce the flowable amniotic composition. The amniotic composition may comprise approximately 2.7 million viable cells per milliliter. The viability of the cells may be substantially stable for at least six months at −18° C. Some preparations of the amniotic composition may have a flowability that may be at least partially characterized by a viscosity suitable for delivery to the target site through at least a 22 gauge needle.
